- Home
- AUID vs OTLK Comparison
AUID vs OTLK Comparison
Compare AUID & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- OTLK
- Stock Information
- Founded
- AUID 2009
- OTLK 2010
- Country
- AUID United States
- OTLK United States
- Employees
- AUID N/A
- OTLK N/A
- Industry
- AUID Computer Software: Prepackaged Software
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUID Technology
- OTLK Health Care
- Exchange
- AUID Nasdaq
- OTLK Nasdaq
- Market Cap
- AUID 47.3M
- OTLK 48.3M
- IPO Year
- AUID N/A
- OTLK 2016
- Fundamental
- Price
- AUID $2.95
- OTLK $1.02
- Analyst Decision
- AUID
- OTLK Buy
- Analyst Count
- AUID 0
- OTLK 5
- Target Price
- AUID N/A
- OTLK $8.50
- AVG Volume (30 Days)
- AUID 49.0K
- OTLK 8.0M
- Earning Date
- AUID 11-06-2025
- OTLK 08-14-2025
- Dividend Yield
- AUID N/A
- OTLK N/A
- EPS Growth
- AUID N/A
- OTLK N/A
- EPS
- AUID N/A
- OTLK N/A
- Revenue
- AUID $2,189,524.00
- OTLK $1,505,322.00
- Revenue This Year
- AUID N/A
- OTLK N/A
- Revenue Next Year
- AUID N/A
- OTLK $484.88
- P/E Ratio
- AUID N/A
- OTLK N/A
- Revenue Growth
- AUID 295.86
- OTLK N/A
- 52 Week Low
- AUID $2.74
- OTLK $0.79
- 52 Week High
- AUID $9.58
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- AUID 34.12
- OTLK 36.21
- Support Level
- AUID $2.74
- OTLK $1.02
- Resistance Level
- AUID $3.14
- OTLK $1.19
- Average True Range (ATR)
- AUID 0.38
- OTLK 0.14
- MACD
- AUID -0.12
- OTLK -0.01
- Stochastic Oscillator
- AUID 11.08
- OTLK 53.49
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.